Graeme Bilbe

Dr Bilbe has the overall responsibility for advancing the discovery and development of new treatments for neglected diseases and building DNDi’s project portfolio.

Prior to joining DNDi in 2012, Dr. Bilbe was Global Head of Neuroscience Discovery at Novartis tasked with discovery and early development to proof of concept testing of novel treatments for brain diseases. During his scientific leadership of Novartis Neuroscience Discovery, he and scientific teams participated in development and registration of new therapies for Alzheimer’s and Parkinson’s disease and Multiple Sclerosis. Under Dr. Bilbe’s leadership, the Neuroscience Discovery group built and developed a portfolio of novel therapies up to clinical efficacy testing for Parkinson’s disease, Fragile X Mental Retardation, cognitive disorders, gastroesophageal reflux disease, epilepsy and chronic pain states. Dr. Bilbe held executive leadership positions both within the Novartis Institutes for Biomedical Research as well as the Novartis Franchise Board for Neuroscience and was a visiting Professor at the University of Liverpool.

He currently is a member of several Scientific Advisory Boards for Biotech Companies, Public Institutions and TDR of the World Health Organization.  Dr. Bilbe completed post-doctoral fellowships at the Zentrum for Molecular Biology in Heidelberg and Imperial College, University of London. He received his PhD in Biochemistry from the University of London, Imperial College and his BSc. in Zoology and Biochemistry from the University of Nottingham.